Mankind Pharma

Mankind Pharma is an Indian pharmaceutical company, based at New Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. They are covering Industrial sectors in pharmaceuticals, medical research and laboratories domain. Mankind Pharma Ltd is a private company.
Mankind Pharma was formed in 1991. It started working as a fully integrated pharmaceutical company in 1995 with the contributions of two brothers, R C Juneja and Rajeev Juneja. The seed capital for establishing the company was 50 Lakh. The company was started with 20 employees and launched in two states in the 1st year of its operation.
In 2019, Mankind became the first Indian company and second only in the world to develop and launch Dydrogesterone, a drug used in high risk pregnancies by the brand name Dydroboon. The company acquired Magnet Labs Pvt. Ltd. to enter the antipsychotic segment in 2007. Also it acquired Longifene-an appetite stimulant for children, in January 2010 which was earlier a brand of UCB Belgium.
History.
Mankind Pharma came into existence in 1986, and in 1991, the company was formed into a legal corporation. However, it actively started working as a fully-integrated pharmaceutical company in 1995. Today, Mankind has an employee base of over 14,000 and is racing towards $1 billion.